Triphase Accelerator announced that the FDA has granted marizomib Orphan Drug designation for the treatment of multiple myeloma. Marizomib is a novel, highly potent proteasome inhibitor that is also being evaluated for the treatment of other cancer indications.

RELATED: Hematologic Cancers Resource Center

An intravenous (IV) formulation of marizomib has been evaluated in more than 230 patients across four Phase 1/2 studies, either as a single agent or in combination with dexamethasone or an HDAC inhibitor. Triphase is currently evaluating the IV formulation in an ongoing Phase 2 clinical trial in combination with dexamethasone in a highly refractory multiple myeloma population, including those refractory to carfilzomib.  It is also being tested in a Phase 1/2 study in combination with pomalidomide and dexamethasone in relapsed and

Continue Reading

For more information call (858) 242-1513 or visit

This article originally appeared on MPR